eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica Supplement
Bieżący suplement Archiwum Klinika Oczna
3/2004
vol. 106
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Artykuł oryginalny

Zja­wi­ska im­mu­no­lo­gicz­ne pro­wa­dzą­ce do pa­to­lo­gii fil­mu łzo­we­go. Czy cy­klo­spo­ry­na bę­dzie prze­ło­mem w le­cze­niu ze­spo­łu Sjögre­na? Do­nie­sie­nie wstęp­ne

Agnieszka Kujawa
1
,
Radosław Różycki
1

  1. Z Kliniki Okulistycznej Wojskowego Instytutu Medycznego w Warszawie
KLINIKA OCZNA 2004, Supl. 3: S489–S491
Data publikacji online: 2022/12/29
Pełna treść artykułu Pobierz cytowanie
 


Purpose
The purpose of this study is to examine the new way in the casual treatment, resulting in the normalization of immunological processes on the ocular surface.

Material and methods
5 patients (4 women and 1 men with mean age of 55,5 years, range 45 to 59 years) with Sjögren’s syndrome – type dry eye, were included in the study. Patients received topically 0,05% cyclosporine, ophthalmic emulsion twice a day for a 6 months. The severity of patients complaints was evaluated according to the Dr. Mann Pharma / Bausch & Lomb’s record.

Results
Schirmer test II values, and lyzamine green staining scores, were evaluated priori to treatment and 6 months after the start. At the beginning of the study (day 0) the Schirmer test II values ranged from 1 to 5 mm (mean – 2,2 mm). Break-up-time ranged from 3 to 6 sec (mean – 4,8 sec). In all of 5 cases lyzamine green staining scores were 9. On month 6th, all of 5 patients had significant differences, compared to their baseline measurements in term of above mentioned parameters. The Schirmer test II values ranged from 8 to 12 mm (mean – 10,3 mm). Break-up-time ranged from 9 to 13 sec (mean – 11,2 sec), lyzamine green staining scores ranged from 2 to 3 points (mean – 2,7).

Conclusions
0,05% cyclosporine, ophthalmic emulsion had a beneficial effect both on the subjective and objective clinical parameters of dry eye patients. The final conclusions must be supported by more cases.

© 2024 Termedia Sp. z o.o.
Developed by Bentus.